» Articles » PMID: 17635612

Interleukin-21 Differentially Affects Human Natural Killer Cell Subsets

Overview
Journal Immunology
Date 2007 Jul 20
PMID 17635612
Citations 35
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-21 (IL-21) is a cytokine with pleiotropic effects on various cell types including dendritic cells, B cells, T cells and natural killer (NK) cells. To evaluate if IL-21 affects human NK cell subpopulations in a similar fashion, functional studies were performed on CD56(dim) and CD56(bright) NK cells, both bearing IL-21 receptors at identical densities. Stimulation with IL-21 strongly induced proliferation of CD56(bright) NK cells and cytotoxicity against K562 target cells was preferentially augmented in CD56(dim) NK cells. In contrast, stimulation with IL-2 and IL-21 alone or in combination failed to induce interferon-gamma and tumour necrosis factor-alpha production in the two NK cell subsets. Intracellular analysis of signal transducer and activator of transcription (STAT) proteins revealed that IL-21 by itself induces phosphorylation of STAT1 and STAT3 in CD56(dim) NK cells, and to an even higher degree in CD56(bright) NK cells. In this CD56(bright) NK cell population alone, IL-2 weakly phosphorylated STAT1 and STAT3, which was further increased when cells were treated with the combination of both cytokines. In contrast, STAT5 was strongly phosphorylated only in CD56(bright) NK cells by low-dose IL-2, while IL-21 did not affect STAT5 at all. In summary, we present data indicating that the NK-cell-directed cytokines IL-2 and IL-21 not only affect functions in NK cell subpopulations differently but can also act additively.

Citing Articles

Interleukin signaling in the regulation of natural killer cells biology in breast cancer.

Xu J, Gao H, Azhar M, Xu H, Chen S, Li M Front Immunol. 2024; 15:1449441.

PMID: 39380989 PMC: 11459090. DOI: 10.3389/fimmu.2024.1449441.


Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.

Shanley M, Daher M, Dou J, Li S, Basar R, Rafei H Cancer Cell. 2024; 42(8):1450-1466.e11.

PMID: 39137729 PMC: 11370652. DOI: 10.1016/j.ccell.2024.07.007.


From bench to bedside: the past, present and future of IL-21 immunotherapy.

Kim A, Zhao L, Patel T, Bailey C, Bai Q, Wakefield M Med Oncol. 2024; 41(7):181.

PMID: 38900341 DOI: 10.1007/s12032-024-02404-7.


Therapeutic potential of interleukin-21 in cancer.

Isvoranu G, Chiritoiu-Butnaru M Front Immunol. 2024; 15:1369743.

PMID: 38638431 PMC: 11024325. DOI: 10.3389/fimmu.2024.1369743.


Outlining the skin-homing and circulating CLANK cells in patients with severe atopic dermatitis.

de Lima J, Emidio Teixeira F, Ramos Y, de Carvalho G, Castelo Branco A, Pereira N Sci Rep. 2024; 14(1):2663.

PMID: 38302650 PMC: 10834414. DOI: 10.1038/s41598-024-53224-8.


References
1.
Arnon T, Achdout H, Levi O, Markel G, Saleh N, Katz G . Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol. 2005; 6(5):515-23. DOI: 10.1038/ni1190. View

2.
Fehniger T, Shah M, Turner M, VanDeusen J, Whitman S, Cooper M . Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol. 1999; 162(8):4511-20. View

3.
Strengell M, Matikainen S, Siren J, Lehtonen A, Foster D, Julkunen I . IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol. 2003; 170(11):5464-9. DOI: 10.4049/jimmunol.170.11.5464. View

4.
Smyth M, Wallace M, Nutt S, Yagita H, Godfrey D, Hayakawa Y . Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer. J Exp Med. 2005; 201(12):1973-85. PMC: 1364507. DOI: 10.1084/jem.20042280. View

5.
Sivori S, Cantoni C, Parolini S, Marcenaro E, Conte R, Moretta L . IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. Eur J Immunol. 2003; 33(12):3439-47. DOI: 10.1002/eji.200324533. View